Safety Considerations for IL-17 Inhibitors in Psoriasis

This episode, titled ‘Safety Considerations for IL-17 Inhibitors in Psoriasis,’ the expert faculty focuses on the safety profile of IL-17 inhibitors in psoriasis, highlighting both class-wide considerations and differences among individual therapies. The panelists emphasize that modern biologics targeting the IL-17 pathway are generally well tolerated, with favorable safety profiles compared with earlier generations of systemic therapies.

The expert dermatologists discuss how there is an increased risk of mild fungal infections, such as tinea and candidiasis, which is a known class effect related to IL-17 inhibitors. They note that these infections are typically manageable, and often occur early in treatment without recurring in most patients. This safety signal reflects the targeted nature of IL-17 inhibition rather than broad immunosuppression.

The panelists also address the potential association between IL-17 inhibitors and inflammatory bowel disease (IBD), including both exacerbation of preexisting disease and possible new onset. The faculty highlights the importance of screening for personal and family history of IBD and incorporating this information into treatment selection and patient counseling. Emerging insights into mechanistic differences within the IL-17 pathway suggest that variations in cytokine targeting may influence these risks, although this remains an area of ongoing research. The expert faculty reinforces the importance of balancing efficacy with safety while tailoring treatment decisions to individual patient profiles in psoriasis care.

In the next episode, ‘Managing Treatment Failure in Psoriasis,’ panelists examine strategies for managing treatment failure in psoriasis, including differentiating primary and secondary non-response and optimizing therapy. It highlights the importance of patient-centered decision-making and the potential value of initiating treatments early to improve long-term outcomes.